224 related articles for article (PubMed ID: 33899152)
1. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
Buhl T; Rosmarin D; Serra-Baldrich E; Fernandez-Peñas P; Igarashi A; Konstantinou MP; Chen S; Lu N; Pierce E; Casillas M
Dermatol Ther (Heidelb); 2021 Jun; 11(3):971-982. PubMed ID: 33899152
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
Thyssen JP; Buhl T; Fernández-Peñas P; Kabashima K; Chen S; Lu N; DeLozier AM; Casillas M; Ständer S
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1599-1611. PubMed ID: 34275122
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
Reich K; DeLozier AM; Nunes FP; Thyssen JP; Eichenfield LF; Wollenberg A; Ross Terres JA; Watts SD; Chen YF; Simpson EL; Silverberg JI
J Dermatolog Treat; 2022 May; 33(3):1521-1530. PubMed ID: 33222559
[TBL] [Abstract][Full Text] [Related]
4. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
[TBL] [Abstract][Full Text] [Related]
5. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
6. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
Thyssen JP; Werfel T; Barbarot S; Hunter HJA; Pierce E; Sun L; Cirri L; Buchanan AS; Lu N; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2190430. PubMed ID: 36912484
[TBL] [Abstract][Full Text] [Related]
7. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Silverberg JI; Simpson EL; Wollenberg A; Bissonnette R; Kabashima K; DeLozier AM; Sun L; Cardillo T; Nunes FP; Reich K
JAMA Dermatol; 2021 Jun; 157(6):691-699. PubMed ID: 33978711
[TBL] [Abstract][Full Text] [Related]
8. Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
Masuda K; Delozier AM; Kolodsick J; Buchanan A; Pink AE; Sun L; Wang Z; Stingeni L; Thac I D
Eur J Dermatol; 2022 Apr; 32(2):237-243. PubMed ID: 35866910
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7.
Silverberg JI; Simpson EL; Thyssen JP; Werfel T; Cardillo TE; Colvin S; Pierce E; Chen YF; Chen S; Eichenfield L
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1036-1045. PubMed ID: 36514996
[TBL] [Abstract][Full Text] [Related]
10. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
[TBL] [Abstract][Full Text] [Related]
11. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
Bieber T; Thyssen JP; Irvine AD; Tsunemi Y; Chen YF; Sun L; Schloebe A; Riedl E; Cork MJ
Clin Exp Dermatol; 2023 Jul; 48(8):881-888. PubMed ID: 37032446
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
Wollenberg A; Simon D; Kulthanan K; Figueras-Nart I; Misery L; Tangsirisap N; Spina L; Lu N; Grond S; Eyerich K
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):695-702. PubMed ID: 38041556
[TBL] [Abstract][Full Text] [Related]
13. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
Silverberg JI; Boguniewicz M; Waibel J; Weisman J; Strowd L; Sun L; Ding Y; Feely M; Nunes FP; Simpson EL
Dermatol Ther (Heidelb); 2022 Jan; 12(1):137-148. PubMed ID: 34846636
[TBL] [Abstract][Full Text] [Related]
14. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.
Bieber T; Katoh N; Simpson EL; de Bruin-Weller M; Thaçi D; Torrelo A; Sontag A; Grond S; Issa M; Lu X; Cardillo T; Holzwarth K; Thyssen JP
J Dermatolog Treat; 2023 Dec; 34(1):2161812. PubMed ID: 36546346
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL; Lacour JP; Spelman L; Galimberti R; Eichenfield LF; Bissonnette R; King BA; Thyssen JP; Silverberg JI; Bieber T; Kabashima K; Tsunemi Y; Costanzo A; Guttman-Yassky E; Beck LA; Janes JM; DeLozier AM; Gamalo M; Brinker DR; Cardillo T; Nunes FP; Paller AS; Wollenberg A; Reich K
Br J Dermatol; 2020 Aug; 183(2):242-255. PubMed ID: 31995838
[TBL] [Abstract][Full Text] [Related]
16. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.
Wollenberg A; Lio P; Kleyn E; Bissonnette R; Jose Rueda M; Casillas M; Chen YF; Lu N; Schloebe A; Simpson E
Eur J Dermatol; 2022 Jul; 32(4):522-529. PubMed ID: 36301752
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
19. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients.
Radi G; Simonetti O; Rizzetto G; Diotallevi F; Molinelli E; Offidani A
Healthcare (Basel); 2021 Nov; 9(11):. PubMed ID: 34828623
[No Abstract] [Full Text] [Related]
[Next] [New Search]